The primary therapeutic use of Amidalin is commonly used across domains where additional symptomatic support is needed for symptoms related to inflammatory or irritative states affecting the oral cavity and throat. This local treatment supports the patient during difficult episodes by easing distress in situations where patients experience throat discomfort. This may be part of symptomatic management in appropriate clinical contexts.

The medicine may assist with conditions characterized by periods of heightened symptoms, including pharyngitis, tonsillitis, minor stomatitis, and gingivitis. It helps address symptom clusters that may become intense or disruptive, such as acute pain, soreness, and painful swallowing (odynophagia).

This dual action offers symptomatic relief that helps patients cope more steadily when symptoms become more noticeable. It assists with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact: Supportive Management for Painful Swallowing (Odynophagia)

“Amidalin is considered relevant when supportive symptom management is appropriate, especially during episodes of localized inflammation.”

The medicine may assist with the acute physical discomfort and functional strain associated with inflamed throat tissues.

Who Can and Cannot Use Amidalin? (Official Eligibility Rules)

The population eligibility for Amidalin (Benzocaine / Tyrothricin) is determined by regulatory requirements, focusing on age, allergy status, and specific underlying conditions. Use is generally approved for adults and adolescents.

---

Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated and must not be used in the following groups:

• Children Under 3 Years of Age: Use is prohibited due to documented safety concerns, including the risk of methemoglobinemia associated with benzocaine.
• Known Hypersensitivity: Patients with a documented allergy to benzocaine, tyrothricin, or any other component of the product.
• History of Methemoglobinemia: Individuals with a history of or suspected methemoglobinemia.
• Specific Metabolic Disorders: Contraindicated in patients with rare hereditary problems like fructose intolerance or glucose-galactose malabsorption (for lozenge form).

---

Populations Requiring Conditional or Restricted Use

• Pregnancy and Lactation: Amidalin is not recommended for use during pregnancy or while breastfeeding unless a healthcare professional determines that the benefit outweighs the potential risk.
• Older Adults and Specific Comorbidities: Use requires caution in older adults and patients with underlying conditions such as G6PD deficiency, severe heart problems, or swallowing difficulties, due to increased risk of complications from the benzocaine ingredient.

Interactions with other medicines and products

This section describes interactions documented in official government regulatory sources for Amidalin, a product containing Benzocaine and Tyrothricin. Due to the topical, oromucosal administration, the Tyrothricin component exhibits minimal systemic absorption, leading to an absence of documented systemic metabolic or pharmacokinetic interactions with other medicinal products.

Pharmacodynamic Interaction Risk

The primary interaction concern relates to the additive pharmacodynamic effect of the Benzocaine component. Co-administration with other agents known to induce methemoglobinemia, such as Dapsone or Nitrate derivatives, may increase the risk of this serious blood disorder. Regulatory documentation notes a general lack of reported exposure-altering interactions for the combination product.

Administration and Population Constraints

The local anesthetic effect of Benzocaine imposes a timing rule requiring food and drink to be avoided immediately following administration to prevent injury to the temporarily numbed area. Furthermore, official government restrictions mandate that oral Benzocaine products are not to be used in children younger than 2 years due to the significantly heightened, life-threatening risk of methemoglobinemia within this population.

Mechanism 1: Interrupting Nociceptive Signal Transmission

This domain covers the pharmacodynamic action of Benzocaine, which directly targets voltage-gated sodium channels ( Na v) on peripheral sensory neurons. By reversibly blocking the channels and preventing the essential influx of Na^+ ions, the mechanism functionally deactivates the nociceptive signaling pathway. This results in the functional stabilization of the neuronal membrane and the interruption of signal transmission. The mechanism differs fundamentally from approaches that modulate the chemical transmission of signals or dampen inflammatory mediator synthesis.

Mechanism 2: Localized Microbial Cell Disruption

This domain addresses the action of Tyrothricin, a polypeptide complex that engages in a physicochemical interaction with the bacterial cell membrane of susceptible microorganisms. The peptides physically insert into the lipid bilayer, creating pores that lead to the rapid and irreversible loss of cellular homeostasis, culminating in bacterial cell lysis. This mechanism is based on direct cytotoxic action, differentiating it from approaches that rely on biochemical inhibition of internal bacterial processes. This action supports a localized reduction in the microbial load on the oropharyngeal mucosa.

Mechanism 3: Dual-System Complementary Action

Amidalin utilizes a fixed-combination, dual-mechanism approach, where two separate active ingredients act on two fundamentally different biological systems: peripheral nervous transmission and microbial cellular integrity. Their mechanisms operate independently and in parallel at the site of application. This combination engages both systems, resulting in concurrent functional deactivation of sensory input and localized microbial load reduction.

Amidalin is an oromucosal preparation intended for localized administration to the throat and mouth. The preparation is administered via the oral route, with the lozenge designed to be dissolved slowly in the mouth, not chewed or swallowed whole, a procedural step that ensures the topical delivery of its active components.

The dosing regimen for adults and children 12 years of age and older is one lozenge per dose, taken at a frequency of every three hours. There is a clear maximum limit, stating that an individual should not exceed 8 lozenges in any 24-hour period. For children aged 3 to 11 years, the maximum daily dose is adjusted to 6 lozenges in a 24-hour period, and the medicine is not permitted for use in children under 3 years of age.

Administration requires adherence to specific timing constraints. It is required to avoid consuming food or drink directly after using the lozenge. Furthermore, the preparation is designated for short-term use only, with instructions advising that it should not be administered for longer than five consecutive days. If a satisfactory response is not observed within two days of initiating the regimen, continuation of use should be reconsidered, maintaining the focus on a controlled, time-limited course.

Research Evidence for Acute Sore Throat and Pharyngitis

The evidence base for research exploring the fixed combination of Amidalin was studied for outcomes related to acute throat symptoms, focusing primarily on uncomplicated sore throat and pharyngitis. The evidence base was evaluated in settings that include short-term, placebo-controlled randomized clinical trials (RCTs) investigating symptom management. These studies were conducted during periods of increased symptom activity and typically applied in studies examining patient-reported experiences of throat discomfort. The goal of this research was to observe how symptoms were assessed in the observed populations when assigned the medicine or an inactive lozenge.

Researchers examined outcomes related to physical discomfort, particularly how patients rated their pain and their functional status related to swallowing. Research highlights changes measured during the study period over the course of the acute episode. This evidence contributes to understanding symptom patterns over short time intervals, but research does not determine whether an individual will respond similarly to the group findings.

Study Design and Quality of Evidence

Regulated research for this medicine involves the use of a placebo group—a practice considered standard for evaluating symptomatic treatments. This design allows researchers to monitor patient-reported outcomes over time in the group assigned the active ingredients versus the group assigned placebo. The overall evidence level for symptomatic use is generally considered Moderate. This grading reflects the consistency of the findings from high-quality RCTs in the management of acute symptoms, but also accounts for the short duration of the follow-up periods and the reliance on synthesis across trials of both the full fixed combination and its primary components.

Key Limitations and Remaining Research Gaps

Clinical research primarily was observed in adult outpatients presenting with symptoms. Data for certain groups remain insufficient. For instance, limited information for long-term outcomes is available for older adults, and there are few data available for children. A key limitation is that results apply only to the populations studied, which were largely adults with non-complicated, non-streptococcal forms of the condition. Comparative evidence is lacking for studies that directly evaluate Amidalin against other treatments in identical trial settings.

The studies do not determine the medicine’s role in the management of complicated or severe bacterial infections, as these populations were not the primary focus of the research. Consequently, the research contributes to the broader evidence landscape but leaves long-term effects not fully established and subgroup findings remain uncertain.

Key Studies & References

1. Study Details | NCT03323528 | Safety and Efficacy of a Sore Throat Lozenge DORITHRICIN in Patients With Acute Pharyngitis
2. Benzocaine Oral Lozenges (General Drug Information on Component)

Common questions about Amidalin (FAQ)

---

Q: What is the main difference between Amidalin and other similar medicines?

Official information indicates that Amidalin is a fixed-combination medicine. This means it contains two distinct active ingredients—a local anesthetic to provide immediate pain relief and a topical antibiotic to reduce the localized presence of susceptible microorganisms. This dual mechanism of action is the defining characteristic of this type of product.

---

Q: How quickly can someone expect to feel the effects of Amidalin?

The local anesthetic component, Benzocaine, is described in official labeling as providing rapid relief by quickly numbing the treated area. The duration of this local effect is typically consistent with the product's recommended dosing interval.

---

Q: Is it possible for Amidalin to interact with common over-the-counter pain relievers?

Official labeling states that the Tyrothricin component is minimally absorbed into the bloodstream. Due to this localized action, there is generally an absence of documented systemic metabolic or pharmacokinetic interactions with other medicines, including common pain relievers taken by mouth.

---

Q: Can elderly patients use Amidalin safely?

Regulatory documents require that use in older adults proceed with caution. This is because this population may be at an increased risk of complications associated with the Benzocaine ingredient. Furthermore, available research data contains limited information regarding the long-term outcomes of using this medicine in older adults.

---

Q: How does Amidalin interact with herbal supplements like St. John's Wort?

Official product information notes that the medicine is minimally absorbed systemically, meaning very little of the active ingredients enter the bloodstream. Therefore, there are no documented systemic metabolic or pharmacokinetic interactions with other products, including most oral herbal supplements.

---

Q: Is it normal to feel tired or drowsy when first starting Amidalin?

Drowsiness is not typically listed as a common side effect of Amidalin. However, official safety documentation lists unusual tiredness or fatigue as a potential symptom of methemoglobinemia, a rare but serious blood disorder associated with the Benzocaine component.

---

Q: Can Amidalin be used by people who have existing liver problems?

Regulatory documents note that one active ingredient has been associated with liver concerns when used in non-topical routes. Because of this, official information advises that individuals with pre-existing liver conditions should seek guidance from a healthcare professional regarding the suitability of Amidalin for their situation.

---

Q: Does Amidalin have any effects on blood pressure?

The medicine is not known to directly affect blood pressure. However, a rapid heart rate (tachycardia) is listed in official safety information as a symptom that may be associated with the rare, serious side effect of methemoglobinemia.

---

Q: Are there specific warnings about Amidalin and driving or operating machinery?

The official Summary of Product Characteristics (SmPC) states that, based on the localized action of the drug, it is expected to have no or negligible influence on the ability to drive or use machines.

---

Q: Can Amidalin be used by people with kidney problems?

Official information indicates that one active component has been associated with kidney damage when used in non-topical forms. Individuals with pre-existing kidney conditions should seek guidance from a healthcare professional regarding the suitability of Amidalin for their specific situation.

---

Q: Why is Amidalin only available by prescription?

The regulatory classification (Prescription Only, or Pharmacy Medicine, or Over-the-Counter) is determined by national health authorities. This classification is assigned based on the medicine's ingredients and the level of professional supervision deemed necessary for safe use, especially considering the potential risks associated with the Benzocaine component.

---

Q: Does Amidalin interact with caffeine or energy drinks?

Due to the minimal systemic absorption of the product, the risk of metabolic interaction with systemic products like caffeine or energy drinks is low or absent, according to official regulatory data. However, the lozenge should not be used immediately before eating or drinking anything.

---

Q: What is the expected duration of the benefit from a single dose of Amidalin?

The local pain-relieving effects of the medicine typically last for a duration that aligns with the established dosing interval. Official instructions state the lozenge may be used every three hours, which reflects the expected duration of the local effect.

---

Q: Are there different strengths of Amidalin available?

The official product documentation clearly defines the specific strength and composition of the lozenge form, including the amount of each active ingredient per unit dose. This ensures consistent administration of the medicine.

---

Q: Can Amidalin be taken with a multivitamin?

Official safety data confirms that there is generally an absence of documented systemic interactions. This is because the medicine is designed for localized action, and minimal amounts of the active ingredients enter the bloodstream, meaning interaction with systemic products like a multivitamin is unlikely.

---

Q: Is Amidalin considered a controlled substance?

The product's active ingredients and local anesthetic/topical antibiotic classification do not fall under the legal definition of a controlled substance according to drug scheduling regulations.

---

Q: Can Amidalin be used if someone has diabetes?

Patient Information Leaflets for the lozenge form often reference the inclusion of sugars (such as sucrose or glucose) as inactive ingredients. Individuals with diabetes should therefore be aware of the carbohydrate content per dose.

Storage and Disposal

Amidalin must be stored according to official regulatory specifications to maintain its stability and effectiveness. The medicine requires storage at Controlled Room Temperature, which is typically 20 C to 25 C (68 F to 77 F).

The product must be protected from moisture and must remain in its original, tight, light-resistant container. As a mandatory safety requirement, Amidalin must be stored out of the sight and reach of children.

Handling Requirement	Environmental Protection
Do not use past the expiration date	Protect from moisture and light
Do not use if the package is damaged	Do not flush down the toilet or sink

Unused or expired Amidalin should be discarded using an official drug take-back program. If no program is available, follow the specified regulatory procedures for mixing the product with an undesirable substance before discarding in household trash.